Skip to main content

Table 3 Characterization of the adverse events registered

From: Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study

Characteristic

Classification

Group A

Group B

Total

Number of events

17 (38.6%)

27 (61.4%)

44 (100%)

Severity

Non-severe

17 (100%)

27(100%)

44 (100%)

Intensity

Grade 1

15 (88.2%)

27 (100%)

42 (95.5%)

Grade 2

2 (11.8%)

--

2 (4.5%)

Causality

Certain

--

11 (40.7%)

11 (25.0%)

Probable

8 (47.1%)

2 (7.4%)

10 (22.7%)

Possible

7 (41.1%)

5 (18.5%)

12 (27.3%)

Unlikely

--

4 (14.8%)

4 (9.1%)

Not related

2 (11.8%)

4 (14.8%)

6 (13.6%)

Unclassifiable

--

1 (3.7%)

1 (2.3%)

Conduct

Pharmacotherapy

3 (17.7%)

1 (3.7%)

4 (9.1%)

Other intervention

--

1 (3.7%)

1 (2.3%)

Observational

14 (82.3%)

25 (92.6%)

39 (88.6%)

Result

Resolved

14 (82.3%)

22 (81.5%)

36 (81.8%)

Improved

1 (5.9%)

--

1 (2.3%)

Persisted

2 (11.8%)

5 (18.5%)

7 (15.9%)

  1. Data are reported as number of events (%)